Are Peptides Legal in Minnesota? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Minnesota as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Minnesota attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Minnesota statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. Minnesota does go further on at least one compound: Human growth hormones, Schedule III, Chorionic gonadotropin (hCG), Schedule III (details below). Minnesota also lists human growth hormone in its own controlled-substance law, on top of the federal rule. The Minnesota Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Minnesota at a glance

State controlled-substances law: Minnesota Statutes chapter 152 (Drugs; Controlled Substances); schedules at Minn. Stat. § 152.02 (revisor.mn.gov)
Human growth hormone under state law: Listed as a controlled substance in state law (Minn. Stat. § 152.02, subd. 3(f)(2)) (revisor.mn.gov)
Research peptides scheduled by the state: Human growth hormones, Schedule III (Minn. Stat. § 152.02, subd. 3(f)(2)) (revisor.mn.gov), Chorionic gonadotropin (hCG), Schedule III (Minn. Stat. § 152.02, subd. 3(f)(3), except approved veterinary products) (revisor.mn.gov)
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy's January 2026 newsletter says the Board is aware of multiple reports of potentially inappropriate use or distribution of semaglutide and tirzepatide injectables, that compounded GLP-1s and unapproved compounded combinations continue to be an issue including professionals prescribing outside their scope, and that any medication dispensed through a medspa or lifestyle clinic must carry a patient-specific label with the same information as a pharmacy label. No standalone Minnesota statement on semaglutide salt forms was found (2026-01) (mn.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Minn. Stat. § 147.033 says a physician-patient relationship may be established through telehealth and holds telehealth to the same standard of care as in-person care, with no in-person examination requirement. The documented-evaluation rule in § 151.37 applies to controlled substances and a few named drug classes, not to GLP-1 drugs. (revisor.mn.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Minnesota, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Minnesota:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Minnesota. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Minnesota law adds

Minnesota's controlled-substances law (Minnesota Statutes chapter 152 (Drugs; Controlled Substances); schedules at Minn. Stat. § 152.02) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (revisor.mn.gov)

Compounds Minnesota has scheduled or restricted

Human growth hormones, Schedule III (Minn. Stat. § 152.02, subd. 3(f)(2)) (revisor.mn.gov)
Chorionic gonadotropin (hCG), Schedule III (Minn. Stat. § 152.02, subd. 3(f)(3), except approved veterinary products) (revisor.mn.gov)

Human growth hormone

Minnesota lists human growth hormones as a Schedule III controlled substance in its own statute, alongside anabolic steroids and chorionic gonadotropin. This goes beyond federal law, where HGH is not scheduled. (Minn. Stat. § 152.02, subd. 3(f)(2)) (revisor.mn.gov)

Compounded semaglutide and tirzepatide

2026-01. The Board of Pharmacy's January 2026 newsletter says the Board is aware of multiple reports of potentially inappropriate use or distribution of semaglutide and tirzepatide injectables, that compounded GLP-1s and unapproved compounded combinations continue to be an issue including professionals prescribing outside their scope, and that any medication dispensed through a medspa or lifestyle clinic must carry a patient-specific label with the same information as a pharmacy label. No standalone Minnesota statement on semaglutide salt forms was found. (mn.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Minnesota medical board guidance specific to peptide therapy was located. A Minnesota prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Minnesota

Possessing an unscheduled research peptide is not a controlled-substance offence in Minnesota, but Minn. Stat. § 151.37, subd. 1 makes it unlawful to possess, sell or distribute a legend (prescription-only) drug except as the chapter allows, so possessing a prescription-only peptide such as semaglutide without a prescription can itself be an offence, and hCG and HGH are Schedule III under § 152.02. (revisor.mn.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Minnesota is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Minn. Stat. § 147.033 says a physician-patient relationship may be established through telehealth and holds telehealth to the same standard of care as in-person care, with no in-person examination requirement. The documented-evaluation rule in § 151.37 applies to controlled substances and a few named drug classes, not to GLP-1 drugs. (revisor.mn.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Minnesota law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Minnesota

2025-02-19. Minnesota's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. Blog claims that a 2025 bill gave the boards new medspa audit powers are wrong; that bill concerns health care entity ownership reporting and was still in committee in February 2026. No Minnesota attorney general or medical board action specific to peptides or compounded GLP-1s was found.

Frequently asked questions

Is BPC-157 legal in Minnesota?

Minnesota has not scheduled BPC-157, so possessing it is not a Minnesota offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Minnesota?

Yes. Minn. Stat. § 147.033 says a physician-patient relationship may be established through telehealth and holds telehealth to the same standard of care as in-person care, with no in-person examination requirement. The documented-evaluation rule in § 151.37 applies to controlled substances and a few named drug classes, not to GLP-1 drugs. The Minnesota Board of Pharmacy position on compounded versions: The Board of Pharmacy's January 2026 newsletter says the Board is aware of multiple reports of potentially inappropriate use or distribution of semaglutide and tirzepatide injectables, that compounded GLP-1s and unapproved compounded combinations continue to be an issue including professionals prescribing outside their scope, and that any medication dispensed through a medspa or lifestyle clinic must carry a patient-specific label with the same information as a pharmacy label. No standalone Minnesota statement on semaglutide salt forms was found.

Is HGH legal in Minnesota?

Only with a valid prescription. Minnesota lists human growth hormone as a controlled substance and federal law, 21 U.S.C. section 333(e), separately makes distribution or possession for a non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Minnesota fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.